Toward elimination and eradication of hepatitis B
- PMID: 20136972
- DOI: 10.1111/j.1440-1746.2009.06165.x
Toward elimination and eradication of hepatitis B
Abstract
Hepatitis B virus (HBV) causes important human health problems. It has infected one-third of the world's population and approximately 360 million people are chronic carriers. Worldwide, 0.5-1.2 million deaths are attributed to HBV infection annually. Therefore, global control of HBV infection is important. HBV infection can be intervened by interrupting routes of transmission, treating the chronically infected, and preventing the susceptibles with immunoprophylaxis. All these measures are effective. Nevertheless, although pegylated interferons or nucleos(t)ide analogs are effective for the treatment of chronic hepatitis B, chronic carriage of HBV is not easy to eliminate, as revealed by the frequent persistence of hepatitis B surface antigen, despite satisfactory responses to these treatments. On the other hand, hepatitis B vaccination has been shown to preclude HBV infection effectively. This is particularly true for pre-exposure prophylaxis. Worthy of note is the universal vaccination of newborn infants. This is the most effective means of preventing HBV infection, especially for those born to HBV carrier mothers. To eliminate and eradicate hepatitis B, first, HBV in the chronically infected should be eradicated or strongly and efficiently suppressed, so that the infection does not spread rampantly. Second, all the transmission routes should be interrupted. Lastly, but most effectively, is to immunize all susceptibles. The difficulties and possible solutions of each approach are discussed. In conclusion, the existing means to prevent and treat HBV infection render our goal toward eliminating and eradicating hepatitis B possible, although it will take much time and effort to achieve this objective.
Similar articles
-
Hepatitis B virus infection.Semin Fetal Neonatal Med. 2007 Jun;12(3):160-7. doi: 10.1016/j.siny.2007.01.013. Epub 2007 Feb 28. Semin Fetal Neonatal Med. 2007. PMID: 17336170 Review.
-
Hepatitis B virus genotypes: a South Pacific perspective.Pac Health Dialog. 2001 Mar;8(1):188-92. Pac Health Dialog. 2001. PMID: 12017822
-
Hepatitis B virus: from diagnosis to treatment.Pathol Biol (Paris). 2010 Aug;58(4):245-53. doi: 10.1016/j.patbio.2010.05.002. Epub 2010 Jul 1. Pathol Biol (Paris). 2010. PMID: 20580167 Review.
-
Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis.Hepatology. 1997 Sep;26(3):786-91. doi: 10.1002/hep.510260336. Hepatology. 1997. PMID: 9303514
-
Hepatitis B--an important public health issue.Clin Lab. 2001;47(1-2):51-5. Clin Lab. 2001. PMID: 11214223 Review.
Cited by
-
Anxiety disorders, COVID-19 fear, and vaccine hesitancy.J Anxiety Disord. 2022 Aug;90:102598. doi: 10.1016/j.janxdis.2022.102598. Epub 2022 Jun 26. J Anxiety Disord. 2022. PMID: 35780664 Free PMC article.
-
Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients.Sci Rep. 2016 Aug 22;6:31349. doi: 10.1038/srep31349. Sci Rep. 2016. PMID: 27546197 Free PMC article.
-
Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes.Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16151-6. doi: 10.1073/pnas.1308049110. Epub 2013 Sep 16. Proc Natl Acad Sci U S A. 2013. PMID: 24043818 Free PMC article.
-
Phage display creates innovative applications to combat hepatitis B virus.World J Gastroenterol. 2014 Sep 7;20(33):11650-70. doi: 10.3748/wjg.v20.i33.11650. World J Gastroenterol. 2014. PMID: 25206271 Free PMC article. Review.
-
Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis.Hepat Mon. 2016 Apr 26;16(4):e35577. doi: 10.5812/hepatmon.35577. eCollection 2016 Apr. Hepat Mon. 2016. PMID: 27257428 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical